State Street SPDR S&P Biotech ETF
228 hedge funds and large institutions have $3.12B invested in State Street SPDR S&P Biotech ETF in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 71 increasing their positions, 60 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
158% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 19
35% more capital invested
Capital invested by funds: $2.32B → $3.12B (+$799M)
18% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 60
13% more funds holding
Funds holding: 201 → 228 (+27)
6.53% more ownership
Funds ownership: 112.16% → 118.69% (+6.5%)
31% less call options, than puts
Call options by funds: $724M | Put options by funds: $1.04B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$155M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$92.8M |
| 3 |
Goldman Sachs
New York
|
+$77.8M |
| 4 |
Barclays
London,
United Kingdom
|
+$37.9M |
| 5 |
Morgan Stanley
New York
|
+$36.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$101M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$46.2M |
| 3 |
O
OrbiMed
New York
|
-$40.3M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$26.6M |
| 5 |
Rafferty Asset Management
New York
|
-$16M |
XBI Hedge Fund Activity: Q3 2016 in Review
228 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2016, worth a combined $3.12B — up 35% from $2.32B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new XBI positions and 19 closed out — a net gain of 30 holders — while 71 added to existing stakes and 60 trimmed.
The largest buyer was Citigroup, adding an estimated $155M. The largest seller was JP Morgan Chase, cutting an estimated $101M.
- 228 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2016, up from 201 in Q2 2016.
- Funds reported $3.12B of State Street SPDR S&P Biotech ETF stock for Q3 2016, up 35% quarter-over-quarter.
- 49 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2016 and 19 closed out, a net change of +30 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2016 was Citigroup, an estimated $155M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2016 was JP Morgan Chase, an estimated $101M sold.
Based on aggregated 13F filings for Q3 2016.